Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday

Cardiol Therapeutics (NASDAQ:CRDL) is projected to issue its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Cardiol Therapeutics Price Performance

NASDAQ:CRDL opened at $1.05 on Wednesday. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.04. The firm has a market capitalization of $117.33 million, a price-to-earnings ratio of -3.50 and a beta of 1.02. Cardiol Therapeutics has a 12-month low of $0.77 and a 12-month high of $1.59.

Institutional Investors Weigh In On Cardiol Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its position in Cardiol Therapeutics by 1,983.0% during the third quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock worth $590,000 after buying an additional 524,598 shares in the last quarter. Citadel Advisors LLC raised its holdings in Cardiol Therapeutics by 1,132.6% in the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after acquiring an additional 425,862 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Cardiol Therapeutics during the 3rd quarter valued at $249,000. Virtu Financial LLC bought a new stake in shares of Cardiol Therapeutics during the 3rd quarter valued at $154,000. Finally, Susquehanna International Group LLP grew its holdings in shares of Cardiol Therapeutics by 366.5% during the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after purchasing an additional 73,375 shares in the last quarter. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the stock. upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cardiol Therapeutics presently has an average rating of “Hold” and a consensus price target of $9.00.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.